M&A Deal Summary |
|
|---|---|
| Date | 2022-04-12 |
| Target | Specific Diagnostics |
| Sector | Medical Products |
| Buyer(s) | bioMerieux |
| Sellers(s) | Telegraph Hill Partners |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1963 |
| Sector | Life Science |
| Employees | 14,147 |
| Revenue | 4.0B EUR (2024) |
bioMerieux is a provider in the field of in vitro diagnostic solutions (reagents, instruments, software) that determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening, monitoring, and cardiovascular emergencies. bioMerieux was founded in 1963 and is based in Marcy-l'Étoile, France.
| DEAL STATS | # |
|---|---|
| Overall | 21 of 21 |
| Sector: Medical Products M&A | 9 of 9 |
| Type: Add-on Acquisition M&A Deals | 17 of 17 |
| State: California M&A | 2 of 2 |
| Country: United States M&A | 8 of 8 |
| Year: 2022 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-02-07 |
Invisible Sentinel
Philadelphia, Pennsylvania, United States Invisible Sentinel, Inc. develops, manufactures and markets innovative and user-friendly molecular diagnostic tools for the rapid, accurate and reliable detection of pathogens and spoilage organisms in food and beverage. |
Buy | $75M |
| Category | Venture Capital Firm |
|---|---|
| Founded | 2001 |
| Size | Middle-Market |
| Type | Sector Focused |
Telegraph Hill Partners is a specialist private equity firm focused on investing in later-stage life science, medical device, and healthcare companies. Prospective companies should be at or near profitability and demonstrate success. Other areas of interest within the healthcare sector include life science technologies, chemistry/reagent suppliers, and information management. Telegraph Hill Partners was formed in 2001 and is based in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 27 of 29 |
| Sector: Medical Products M&A | 13 of 14 |
| Type: Add-on Acquisition M&A Deals | 22 of 24 |
| State: California M&A | 17 of 18 |
| Country: United States M&A | 26 of 28 |
| Year: 2022 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-04-04 |
AltheaDx
San Diego, California, United States AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenetics, or PGx. AltheaDx's product testing portfolio enables personalized therapeutic decisions for patients suffering from some of the most prevalent clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders, and pain. AltheaDx was founded in 1998 and is based in San Diego, California. |
Sell | $65M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-01-09 |
Verogen
San Diego, California, United States Verogen is a developer, manufacturer, and sells forensic genomics products and services, including for next-generation sequencing. Verogen was formed in 2017 and is based in San Diego, California. |
Sell | $150M |
